Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging
Verified January 2013 by Universitaire Ziekenhuizen Leuven
Information provided by (Responsible Party):
Steven Pans, Universitaire Ziekenhuizen Leuven
First received: January 26, 2013
Last updated: January 28, 2013
Last verified: January 2013
Whole body MRI with diffusion weighted imaging is a useful imaging tool
- staging and diagnosis
- therapy monitoring All patients will be scanned before and during treatment. The findings on diffusion weighted imaging will be correlated to the golden standard (computer tomography and MRI (T1 and STIR)).
||Observational Model: Case-Only
Time Perspective: Prospective
||Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI: What is the Added Value of Diffusion Weighted Imaging in Diagnosis and Follow-up
Primary Outcome Measures:
Secondary Outcome Measures:
- Therapy assessment [ Time Frame: 4 years ] [ Designated as safety issue: No ]
Whole body MRI with Diffusion weighted imaging is useful for treatment monitoring in multiple myeloma patients during and after therapy.
Measurement of apparent diffusion coefficient (ADC) and comparison of ADC before, during and after therapy. Correlation of ADC with clinical findings and standard MRI findings.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||March 2013 (Final data collection date for primary outcome measure)
Indolent myeloma patient
Symptomatic Myeloma patient
|Ages Eligible for Study:
||25 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients with clinical and laboratory findings, highly suggestive for multiple myeloma. All patients underwent bone marrow biopsy.
- Patients with clinical and laboratory findings, highly suggestive for multiple myeloma.
- All patients who are not allowed to be scanned on MRI (Pacemaker, implants ed.)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01780766
Universitaire Ziekenhuizen Leuven
||Steven Pans, MD
||Universitaire Ziekenhuizen Leuven
Bannas P, Hentschel HB, Bley TA, Treszl A, Eulenburg C, Derlin T, Yamamura J, Adam G, Stübig T, Kröger N, Weber C. Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation. Eur Radiol. 2012 Sep;22(9):2007-12. doi: 10.1007/s00330-012-2445-y. Epub 2012 Apr 29.
||Steven Pans, Medical Doctor Radiologist, Universitaire Ziekenhuizen Leuven
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 26, 2013
||January 28, 2013
||Belgium: Federal Agency for Medicinal Products and Health Products
Keywords provided by Universitaire Ziekenhuizen Leuven:
Whole body MRI
Diffusion Weighted MRI
Whole body scan
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 21, 2014
Neoplasms, Plasma Cell
Signs and Symptoms
Neoplasms by Histologic Type
Blood Protein Disorders
Immune System Diseases